Viridian Therapeutics, Inc.
VRDN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2 | $3 |
| % Growth | -3.8% | -82.3% | -40.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $2 | $3 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $238 | $160 | $101 | $57 |
| G&A Expenses | $61 | $95 | $35 | $26 |
| SG&A Expenses | $61 | $95 | $35 | $26 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $299 | $255 | $136 | $83 |
| Operating Income | -$299 | -$254 | -$134 | -$80 |
| % Margin | -99,018.2% | -81,035% | -7,579.2% | -2,690.8% |
| Other Income/Exp. Net | $29 | $17 | $4 | $0 |
| Pre-Tax Income | -$270 | -$238 | -$130 | -$79 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$270 | -$238 | -$130 | -$79 |
| % Margin | -89,387.1% | -75,711.5% | -7,329.2% | -2,680.2% |
| EPS | -3.98 | -5.31 | -3.91 | -6.66 |
| % Growth | 25% | -35.8% | 41.3% | – |
| EPS Diluted | -3.98 | -5.31 | -3.91 | -6.66 |
| Weighted Avg Shares Out | 68 | 45 | 32 | 12 |
| Weighted Avg Shares Out Dil | 68 | 45 | 32 | 12 |
| Supplemental Information | – | – | – | – |
| Interest Income | $32 | $19 | $5 | $0 |
| Interest Expense | $3 | $2 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$266 | -$235 | -$129 | -$79 |
| % Margin | -87,967.9% | -74,957% | -7,287.4% | -2,676% |